313679-52-6

Upstream product

• 152438-62-5 (S)-N-[3-Chloro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]carbamic acid 1,1-dimethylethyl ester 
• 127132-32-5 ethyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-O-(phenylmethyl)-L-tyrosinate 
• 174801-33-3 (2S,3S)-N-tert-butoxycarbonyl-3-amino-4-(4-benzyloxyphenyl)-1-chloro-2-hydroxybutane 
• 162536-84-7 tert-butyl (1S)-2-[4-(benzyloxy)phenyl]-1-[(2S)-oxiranyl]ethylcarbamate 
• 78-81-9 isobutylamine 

Downstream Products

• 313679-53-7 t-butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-hydroxypropyl)-carbamate 
• 313681-93-5 tert-butyl N-(1S,2R)-1-[(4-benzyloxy)benzyl]-3-[(5-tert-butyldimethylsilyloxy-2,2-dimethyl)amino]-2-hydroxypropylcarbamate 
• 220871-75-0 tert-butyl (1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-(isobutylamino)propylcarbamate 
• 313679-54-8 C₃₂H₄₁N₃O₈S 
• 313680-04-5 (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}benzyl)-2-hydroxypropylcarbamate 
• 313680-02-3 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{3-[(tert-butoxycarbonyl)amino]propoxy}benzyl)-2-hydroxypropylcarbamate 
• 313680-00-1 (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{2-[(tert-butoxycarbonyl)amino]ethoxy}benzyl)-2-hydroxypropylcarbamate 
• 313680-05-6 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-1-[4-(4-aminobutoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) amino]-2-hydroxypropylcarbamate 
• 313680-03-4 (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-1-[4-(3-aminopropoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate 

Relevant academic research and scientific papers

Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

A novel series of tyrosine-derived HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and two protease inhibitor-resistant viruses. All of the compounds had wild-type antiviral activities that were similar to or greater than several currently marketed HIV protease inhibitors. In addition, a number of compounds in this series were more potent against the drug-resistant mutant viruses than they were against wild-type virus.

Antiviral Compounds

The present application provides compounds and methods of treating viral infections, including viral infections caused by HIV or HTLV.